What is the main purpose of these agreements?

The main purpose of these agreements is to resolve ongoing patent litigation and challenges in the United States related to Gilead's HIV and Hepatitis B medications Descovy®, Vemlidy®, and Odefsey®. The agreements grant licenses to generic manufacturers for the patents covering these drugs.

When will generic versions of these drugs be allowed to enter the U.S. market?

Generic versions of Descovy® and Vemlidy® will be permitted to enter the U.S. market on or after October 31, 2031. For Odefsey®, the entry date is on or after January 31, 2032, though these dates could be earlier under certain circumstances outlined in the agreements.

What does 'non-exclusive license' mean for Gilead's revenue?

A non-exclusive license means Gilead is granting the right to use its patents to multiple generic manufacturers, not just one. While this settles litigation, it also indicates that multiple generic competitors could emerge after the license start dates, potentially impacting future revenue through increased competition, but also providing a predictable timeline for exclusivity until then.

Are these agreements filed with regulatory bodies?

Yes, the agreements will be filed with the U.S. Federal Trade Commission and the U.S. Department of Justice as required by law. This is a standard procedure for patent settlement agreements involving significant pharmaceutical products.

GILD 8-K: Regulation FD

Summary

Gilead Sciences, Inc. (GILD) announced on September 12, 2022, that it has reached agreements with several generic manufacturers to resolve patent litigation concerning its key HIV and Hepatitis B medications: Descovy®, Vemlidy®, and Odefsey®. These agreements grant non-exclusive licenses in the United States for the underlying patents related to tenofovir alafenamide. This resolution is significant for investors as it clarifies the future market entry of generic versions of these important drugs. The licenses begin on October 31, 2031, for Descovy and Vemlidy, and January 31, 2032, for Odefsey, with potential earlier termination under specific conditions. This provides Gilead with a defined period of market exclusivity for these products in the US, mitigating immediate patent challenges and offering a degree of predictability for future revenue streams.

Key Highlights

1Gilead Sciences has settled patent litigation with multiple generic manufacturers (Lupin Ltd., Apotex Inc., Macleods Pharma Ltd., Hetero Labs Ltd., and Cipla Ltd.).
2The settlements resolve challenges related to patents for Descovy®, Vemlidy®, and Odefsey® in the U.S.
3Agreements grant non-exclusive US licenses for tenofovir alafenamide patents.
4Descovy® and Vemlidy® US patent licenses begin October 31, 2031.
5Odefsey® US patent license begins January 31, 2032, with potential for earlier termination.
6Gilead has filed notices of dismissals for the generic manufacturers from the court case.
7This resolution provides a degree of clarity on future generic competition for these key Gilead products.

GILEAD SCIENCES, INC. 8-K Report, Regulation FD Disclosure (Sep 12, 2022)

Summary

Key Highlights

Frequently Asked Questions